Clinical case of rheumatoid arthritis with antiphospholipid antibody syndrome

Cover Page

Cite item

Full Text

Abstract

The article presents a clinical case of development of secondary antiphospholipid syndrome (APS) with early active rheumatoid polyarthritis, complication in the form of acute deep vein thrombosis of forearm on the left and chronic left vein thrombosis of the lower extremity. Patient treatment with methotrexate has developed an infectious complication and resulting in the need to go to therapy of leflunomide. This therapy have positive effect. In a survey of the patient revealed a rare form of adrenal pheochromocytoma confirmed by computed tomography and measurements of plasma normetanephrine, but not accompanied an increase of blood pressure. This article discusses the modern classification of APS, pathogenesis, clinical and laboratory diagnostic criteria, methods of therapy as rheumatoid arthritis, and APS.

About the authors

G. G Arabidze

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: arabidze@mail.ru
д-р мед. наук, проф. каф. госпитальной терапии №2 ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. V Shapchenko

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

канд. мед. наук, ассистент каф. госпитальной терапии №2 ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

O. V Muslimova

Scientific Center for Expertise of Pharmaceuticals for Medical Use of the Ministry of Health of the Russian Federation

мл. науч. сотр. Института клинической фармакологии ФГБУ НЦЭСМП 127051, Russian Federation, Moscow, Petrovskii b-r, d. 8

O. Yu Larina

S.P.Botkin City Clinical Hospital of the Department of Health of Moscow

зав. отд-нием терапии филиала №3 ГБУЗ ГКБ им. С.П.Боткина 125284, Russian Federation, Moscow, 2-i Botkinskii pr-d, d. 5

A. M Sorokoletov

S.P.Botkin City Clinical Hospital of the Department of Health of Moscow

д-р мед. наук, зам. глав. врача по филиалам ГБУЗ ГКБ им. С.П.Боткина 125284, Russian Federation, Moscow, 2-i Botkinskii pr-d, d. 5

References

  1. Каратеев Д.Е., Олюнин Ю.А., Лучихина Е.Л. Новые классификационные критерии ревматоидного артрита ACR/EULAR 2010 - шаг вперед к ранней диагностике. Научно - практ. ревматология. 2011; 49: 10-5.
  2. Калашникова Л.А., Сергеева Е.В., Суворов А.В. и др. Диагностика волчаночного антикоагулянта. Методическое руководство. М.: Принт, 2013.
  3. Кондратьева Л.В., Решетняк Т.М. Антифосфолипидный синдром: диагностика и профилактика тромбозов. Доктор.Ру. 2010; 3 (54): 52-6.
  4. Насонов Е.Л., Баранов А.А., Шилкина Н.П. и др. Патология сосудов при антифосфолипидном синдроме. М.-Ярославль. 1994; с. 29-55.
  5. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно - практ. ревматология. 2013; 51 (6): 8-26.
  6. Николаев О.В., Меньшиков В.В., Калинин А.П. и др. Феохромоцитома. М.: Медицина, 1965; с. 92.
  7. Пиманов С.И., Макаренко У.И. Антифосфолипидный синдром. Справ. поликлин. врача. 2007; 8: 4-10.
  8. Регистр лекарственных средств России. Доктор: Дерматовенерология. 2011; 15: 111-9.
  9. Регистр лекарственных средств России. Доктор: Дерматовенерология. 2011; 15: 281-90.
  10. Федеральное руководство по использованию лекарственных средств. 2014; 15: 429.
  11. Федеральное руководство по использованию лекарственных средств. 2014; 15: 936.
  12. Brandt J.T, Triplett D.A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
  13. Filipowicz-Sosnowska A, Carwolinska H, Stanislawska-Biernat E et al. Clinical, immunological, morphological and immunofluorescent studies in rheumatoid vasculitis patients. Clin Rheumatol 1994; 13: 372 (Abstr.).
  14. Genovese M.C. Treatment of rheumatoid arthritis. In G.S.Firestein et al. (eds). Kelley’s Textbook of Rheumatology, 8th ed. Philadelphia: Saunders Elsevier, 2009; 2: 1119-43.
  15. Gould T et al. Prevalence аnd clinical correlates of anti - phospholipid antibodies in South Africans with systemic lupus erytematosus. Scand J Rheumatol 2006; 35 (1): 29-34.
  16. Erkan D, Pierangeli S.S. (eds.). Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. doi: 10.1007/978-1-4614-3194-7_17. ©Springer Science + Business Media New York 2012.
  17. Jeleniewicz R, Majdan M, Targońska-Stępniak B, Dryglewska M. Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity. Pol Arch Med Wewn 2012; 122 (10): 480-6.
  18. Khamashta M.E et al. Antiphospholipid (Hughes) syndrome. Autoimmunity 2004; 37 (4): 309-12.
  19. Levine J.S et al. Catastrophic Antiphospholipid syndrome. N Engl J Med 2002; 346 (10): 752-63.
  20. Lesley J. Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis. Drugs 2013; 73: 857-74.
  21. Mehdi A, Uthman I, Khamashna M. Treatment of antiphospholipid syndrome. Int J Clin Rheumatol 2010; 5 (2): 241-54.
  22. Miyakis S, Lockshin M, Atsumi T et al. International consensus statement on an update of the classifi cation criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
  23. Montoya R.C, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Advances in Hematol 2012. Article ID 856341. Doi:10,1155/2012/856341.
  24. Palomo I, Pinochet C, Alarcón M et al. Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis. J Clin Lab Anal 2006; 20 (5): 190-4.
  25. Pincus T, Cronstein B, Braun J. Methotrexate - the anchor drug - an introduction. Clin Exp Rheumatol 2010; 28: S1-S2.
  26. Radway-Bright E.L. Antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rhematology (Oxford) 2000; 39 (4): 427-31.
  27. Cervera R, Piette J-C, Font J et al. Antiphospholipid Syndrome Clinical and Immunologic Manifestations and Patterns of Disease Expression in a Cohort of 1,000 Patients. Arthr Rheum 2002; 4 (46):1019-27.
  28. Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I et al. Evidence - based recommendations for the prevention and long - term management of thrombosis in antiphospholipid antibody - positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 2011; 20: 206-18.
  29. Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol 2001; 19 (5): 561-4.
  30. Smolen J.S, Aletaha D, Bijlsma J.W et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-7.
  31. Smolen J.S, Landewe R, Breedveld F.C et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease - modifying antirheumatic drugs. Ann Rheum Dis 2010. doi: 10.1136/ard.2009.

Copyright (c) 2015 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies